Search

Your search keyword '"Luca, Ceriani"' showing total 221 results

Search Constraints

Start Over You searched for: Author "Luca, Ceriani" Remove constraint Author: "Luca, Ceriani"
221 results on '"Luca, Ceriani"'

Search Results

1. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

2. S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

Catalog

Books, media, physical & digital resources

3. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis

4. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

5. Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma

6. Tc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities

8. Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications

9. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

13. Diagnostic Performance of 18F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis

14. Postoperative thyroglobulin as a yard-stick for radioiodine therapy : decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer

15. Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma

16. Radiomics analysis improves 18FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules

17. Optimal timing and criteria of interim PET in DLBCL: A comparative study of 1692 patients

18. The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review

19. D

20. Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib

21. Author response for 'Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib'

22. International Impact of COVID-19 on the Diagnosis of Heart Disease

23. Radiomics Analysis of [18F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment

24. Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma

25. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

26. Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS

27. Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis

28. HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma

30. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

31. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

33. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

34. CT evaluation of lung infiltrates in the two months preceding the Coronavirus disease 19 pandemic in Canton Ticino (Switzerland): were there suspicious cases before the official first case?

36. An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy

37. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis

38. Author response for 'Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis'

39. Role of18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients

40. Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis

41. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume

42. Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma

43. Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma

44. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA

45. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

46. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA

47. INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY

48. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)

49. Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma

50. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma